Discussions were held on critical importance of early intervention in cancer and its role in improving clinical outcomes

Dr Reddy’s Laboratories hosted the third edition of the Dr Anji Reddy Memorial Lecture, an annual lecture series instituted to honour the memory of the scientist, entrepreneur and philanthropist, Dr K Anji Reddy.

This year, the Dr Anji Reddy Memorial Lecture was delivered by Prof Ashok Venkitaraman, Director, Cancer Science Institute of Singapore and Distinguished Professor of Medicine at the National University of Singapore, on ‘Suppressing the genesis of cancer’. Prof Venkitaraman highlighted the interplay of genetic background and environmental exposures in cancer progression, based on the insights from his research on the BRCA gene, over the past two decades.

Delivering the third Dr Anji Reddy Memorial Lecture, Prof Venkitaraman delved into how tumour suppressive pathways maintain genomic integrity and can be perturbed under both metabolic disorders and harmful environmental stimuli. He emphasised the need for a deeper understanding of the mechanisms governing cancer, involving integrating multiple research expertise like genetics, structural biology, chemistry, and imaging to combat this devastating disease. He also called out the critical importance of early intervention in cancer and its role in improving clinical outcomes.

Dr Gullapalli Nageswara Rao, Founder, LV Prasad Eye Institute in Hyderabad, highlighted Dr Anji Reddy’s instrumental role and how his association with science and research made a remarkable impact on the development and growth of the institute. Reflecting on his cherished memories, work and friendship, Dr Rao emphasised how Dr Reddy’s deep commitment to science, society, and sustainability remains a lasting source of inspiration in the realms of research, affordable healthcare and philanthropy.

GV Prasad, Co-Chairman and MD, Dr Reddy's said, “Dr Anji Reddy’s vision for affordable and accessible medicines was deeply rooted in his commitment to science. His determination to be a pioneer in both science and business has resulted in several industry-first products. His influence has left a strong impression on many towards driving innovation, leveraging science and technology, and working collectively for societal welfare.”

Delivering the closing remarks, Satish Reddy, Chairman, Dr Reddy’s, highlighted the need for pioneering studies to drive novel drug discoveries in life-threatening diseases like cancer. He also shed light on some of the notable work being carried out at Aurigene Oncology Limited, the oncology drug-discovery arm of Dr Reddy’s, in the field of cancer research. He reaffirmed the company’s commitment to pursuing the founder Dr Anji Reddy’s unfinished agenda of new drug discovery and taking it to market.